에 대한 최신 뉴스 RAPT Therapeutics (NASDAQ:RAPT) 주식

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Inc

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

RAPT Therapeutics ( ($RAPT) ) has issued an announcement. RAPT Therapeutics has approved a repricing of underwater options for its employees, signi...

RAPT Therapeutics Reprices Underwater Employee Stock Options

TimesSquare U.S. Small/Mid Cap Growth Q3 2024 Commentary

RAPT Therapeutics (RAPT) and Shanghai Jemincare Pharmaceutical, a subsidiary of Jiangxi Jemincare Group, announced they have entered into an exclus...

Rapt Therapeutics, Jemincare enter exclusive license agreement for JBY1904

RAPT Therapeutics soars as it looks to raise $150M in private placement

An update from RAPT Therapeutics ( ($RAPT) ) is now available. RAPT Therapeutics announced a partnership with Shanghai Jemincare Pharmaceutical for...

RAPT Therapeutics Partners with Jemincare and Secures Funding

RAPT Therapeutics (RAPT) has entered into a securities purchase agreement with a group of accredited investors for the private placement of 100,000...

RAPT Therapeutics prices 100M shares at 85c in private placement

Wells Fargo raised the firm's price target on Rapt Therapeutics (RAPT) to $6 from $4 and keeps an Overweight rating on the shares. With the in-lice...

Rapt Therapeutics price target raised to $6 from $4 at Wells Fargo

RAPT rockets 180% on licensing deal, $150M private placement

RAPT rockets 180% on licensing deal, $150M private placement (update)

ASND

ATRC

AXSM

BMBL

CTXR

CYBR

EXPO

FIVE

FROG

FRPT

FULC

GLBE

HRTX

KRYS

MNOV

MSTR

MTDR

NICE

ONTO

PHAT

RAPT

RGEN

RHHBY

SMAR

SMCI

SNYNF

SYNA

SYRS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

News

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

RAPT Therapeutics Announces $150 Million Private Placement

Agenus

Annovis Bio

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Cue Biopharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Invivyd

Kronos Bio

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Mural Oncology

Ovid Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Repare Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Vigil Neuroscience

Vor Biopharma

Exicure

Wells Fargo

Barclays

Leerink Partners

Berenberg

Comments

RAPT Therapeutics

뉴스

에 대한 최신 뉴스 RAPT Therapeutics (NASDAQ:RAPT) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌